NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis $34.88 -1.05 (-2.92%) Closing price 04:00 PM EasternExtended Trading$34.88 -0.01 (-0.01%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Castle Biosciences Stock (NASDAQ:CSTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Castle Biosciences alerts:Sign Up Key Stats Today's Range$34.24▼$36.2450-Day Range$23.89▼$36.7852-Week Range$17.72▼$44.28Volume318,608 shsAverage Volume396,801 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$42.00Consensus RatingModerate Buy Company Overview Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes. The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions. Castle also offers tests for other cancers, including TissueCypher, which evaluates the risk of progression in patients with Barrett’s esophagus, and DecisionDx-UM for uveal melanoma. Founded in 2008, Castle Biosciences is headquartered in Friendswood, Texas, and primarily serves the U.S. medical and healthcare markets. The company works with dermatologists, oncologists, pathologists and other clinicians by providing test results intended to support personalized patient management. Derek Maetzold serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Castle Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreCSTL MarketRank™: Castle Biosciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 621st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCastle Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCastle Biosciences has a consensus price target of $42.00, representing about 21.8% upside from its current price of $34.47.Amount of Analyst CoverageCastle Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($1.29) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -52.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -52.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.62% of the float of Castle Biosciences has been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 7.36.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 3.91%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.07 News SentimentCastle Biosciences has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Castle Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,083,615.00 in company stock.Percentage Held by Insiders6.10% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSTL Stock News HeadlinesCastle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE PatientsSeptember 28 at 5:06 PM | rttnews.comNew Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's EsophagusSeptember 28 at 7:00 AM | prnewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 29 at 1:00 AM | Altimetry (Ad)Castle Biosciences (NASDAQ:CSTL) Raised to "Buy" at Wall Street ZenSeptember 26 at 1:13 AM | americanbankingnews.comCastle Biosciences, Inc. Announces Publication of New Study Highlighting Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of ...September 25, 2026 | marketscreener.comMCastle Biosciences, Inc.: New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-TxSeptember 25, 2026 | finanznachrichten.deNew Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™September 24, 2026 | prnewswire.comTobin Juvenal Sells 3,306 Shares of Castle Biosciences (NASDAQ:CSTL) StockSeptember 17, 2026 | insidertrades.comSee More Headlines CSTL Stock Analysis - Frequently Asked Questions How have CSTL shares performed this year? Castle Biosciences' stock was trading at $38.90 on January 1st, 2026. Since then, CSTL stock has decreased by 11.4% and is now trading at $34.4690. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) released its earnings results on Thursday, July, 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative trailing twelve-month return on equity of 4.15%. Read the conference call transcript. When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $60 million in an IPO on Wednesday, July 24th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings7/30/2026Today9/29/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CSTL's financial health is in the Green zone, according to TradeSmith. CSTL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:CSTL CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees1,002Year Founded2008Price Target and Rating Average Price Target for Castle Biosciences$42.00 High Price Target$52.00 Low Price Target$35.00 Potential Upside/Downside+20.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.16 million Net Margins-5.43% Pretax Margin-5.37% Return on Equity-4.15% Return on Assets-3.45% Debt Debt-to-Equity Ratio0.02 Current Ratio6.04 Quick Ratio5.85 Sales & Book Value Annual Sales$344.23 million Price / Sales3.10 Cash Flow$1.08 per share Price / Cash Flow32.17 Book Value$16.13 per share Price / Book2.16Miscellaneous Outstanding Shares30,550,000Free Float28,686,000Market Cap$1.07 billion OptionableOptionable Beta0.99 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CSTL) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
